No matches
Pulmonology

Spotlight on Type 2 Inflammation in the Upper and Lower Airways

In this video soundbite from the EAACI 2025 symposium, Dr. Zuzana Diamant explains pathophysiological mechanisms underlying asthma and CRSwNP, and how type 2 inflammatory cytokines drive airway remodelling in patients with severe asthma. Additionally, patients with co-existing asthma and CRSwNP have a higher type 2 inflammatory burden than patients with asthma alone.
Zuzana Diamant
MD, PhD
Zuzana Diamant

Related resources

CRSwNP at Center Stage: Impact of Biologics in Patients with Co-existing Type 2 Asthma

CRSwNP at Center Stage: Impact of Biologics in Patients with Co-existing Type 2 Asthma

expert video
Compounded Burden of Co-existing Type 2 Airway Diseases

Compounded Burden of Co-existing Type 2 Airway Diseases

expert video
FeNO as a Biomarker for Type 2 Asthma

FeNO as a Biomarker for Type 2 Asthma

expert video
ERS 2023 | On-Therapy Remission in Pediatric Asthma: Where Are We Today?

ERS 2023 | On-Therapy Remission in Pediatric Asthma: Where Are We Today?

expert video
IRS-ISIAN 2024 | The Underappreciated Burden of Smell Loss and Congestion in CRSwNP

IRS-ISIAN 2024 | The Underappreciated Burden of Smell Loss and Congestion in CRSwNP

expert video
What contributes more to loss of smell in patients with CRSwNP: nasal obstruction or inflammation?

What contributes more to loss of smell in patients with CRSwNP: nasal obstruction or inflammation?

expert video
ERS 2024 | Pathophysiologic Mechanisms of Airway Remodeling in Severe Asthma

ERS 2024 | Pathophysiologic Mechanisms of Airway Remodeling in Severe Asthma

expert video
ERS-ISIAN 2025 | Type 2 Inflammation: Links with Severe/Uncontrolled CRSwNP

ERS-ISIAN 2025 | Type 2 Inflammation: Links with Severe/Uncontrolled CRSwNP

expert video
IgE as a Biomarker for Type 2 Asthma

IgE as a Biomarker for Type 2 Asthma

expert video
ERS 2023 | Progression of Underlying Disease in Pediatric Severe Asthma

ERS 2023 | Progression of Underlying Disease in Pediatric Severe Asthma

expert video
IRS-ISIAN 2024 | Mechanisms of Smell Loss in CRSwNP: Blockage and Inflammation

IRS-ISIAN 2024 | Mechanisms of Smell Loss in CRSwNP: Blockage and Inflammation

expert video
How does a decrease in smell affect sleep disturbance? Is there any direct relation?

How does a decrease in smell affect sleep disturbance? Is there any direct relation?

expert video
Loss of Smell is a Key Symptom of CRSwNP

Loss of Smell is a Key Symptom of CRSwNP

interactivity
ERS-ISIAN 2025 | Disease Control in CRSwNP

ERS-ISIAN 2025 | Disease Control in CRSwNP

expert video
Airway Remodeling in Type 2 Asthma is Driven by IL-4 and IL-13

Airway Remodeling in Type 2 Asthma is Driven by IL-4 and IL-13

expert video
ERS 2023 | Burden of Underlying Disease in Pediatric Severe Asthma

ERS 2023 | Burden of Underlying Disease in Pediatric Severe Asthma

expert video
IRS-ISIAN 2024 | Targeting Type 2 Inflammation: Managing Smell Loss and Congestion in Patients With Recurrent CRSwNP

IRS-ISIAN 2024 | Targeting Type 2 Inflammation: Managing Smell Loss and Congestion in Patients With Recurrent CRSwNP

expert video
Why did the definition of control in CRSwNP change between EPOS 2020 and EPOS/EUFOREA 2024?

Why did the definition of control in CRSwNP change between EPOS 2020 and EPOS/EUFOREA 2024?

expert video
Understanding IL-33: A Key Factor in COPD Pathogenesis

Understanding IL-33: A Key Factor in COPD Pathogenesis

interactivity
Unraveling the Link of Type 2 Inflammation and Airway Remodeling in Asthma

Unraveling the Link of Type 2 Inflammation and Airway Remodeling in Asthma

expert video
Type 2 Inflammation Mediates Severe Asthma in Pediatric Patients

Type 2 Inflammation Mediates Severe Asthma in Pediatric Patients

expert video
ERS 2023 | Pediatric Asthma Symposium: Patient Case Discussion

ERS 2023 | Pediatric Asthma Symposium: Patient Case Discussion

expert video
IRS-ISIAN 2024 | Emerging Expert Definitions of Remission in CRSwNP

IRS-ISIAN 2024 | Emerging Expert Definitions of Remission in CRSwNP

expert video
When is the right time to consider a biologic in patients with CRSwNP?

When is the right time to consider a biologic in patients with CRSwNP?

expert video
Blood Eosinophils: A Biomarker in COPD

Blood Eosinophils: A Biomarker in COPD

Infographic
ERS 2024 | Understanding Remission as a Treatment Goal in Pediatric Severe Asthma – Patient Case Introduction

ERS 2024 | Understanding Remission as a Treatment Goal in Pediatric Severe Asthma – Patient Case Introduction

expert video
Mucus Plugging as a Potential Target in Asthma Management

Mucus Plugging as a Potential Target in Asthma Management

expert video
Eosinophils as a Biomarker for Type 2 Asthma

Eosinophils as a Biomarker for Type 2 Asthma

expert video
ERS 2023 | Assessing Disease Activity to Better Define On-Treatment Clinical Remission in Pediatric Severe Asthma

ERS 2023 | Assessing Disease Activity to Better Define On-Treatment Clinical Remission in Pediatric Severe Asthma

expert video
Monitoring Lung Function Is an Important Aspect of Pediatric Asthma Management

Monitoring Lung Function Is an Important Aspect of Pediatric Asthma Management

interactivity
What treatments may be needed to achieve remission? And In what percentage of patients could remission be a target?

What treatments may be needed to achieve remission? And In what percentage of patients could remission be a target?

expert video
How do You Define Active Disease (CRSwNP) When Looking at the Nose With an Endoscope?

How do You Define Active Disease (CRSwNP) When Looking at the Nose With an Endoscope?

expert video
ERS 2024 | Panel Discussion: What Might Be Required for On-Therapy Remission in Pediatric Severe Asthma?

ERS 2024 | Panel Discussion: What Might Be Required for On-Therapy Remission in Pediatric Severe Asthma?

expert video
CRSwNP Triathlon: An Interactive Learning Experience

CRSwNP Triathlon: An Interactive Learning Experience

interactivity
Multifaceted Role of IL-13 in Airway Remodeling

Multifaceted Role of IL-13 in Airway Remodeling

expert video
Pediatric Asthma Patient Case Tool: Ash

Pediatric Asthma Patient Case Tool: Ash

interactivity
GINA-Based Opportunities for Improved Outcomes With Effective Management of Pediatric Asthma in Children 6-11 Years of Age

GINA-Based Opportunities for Improved Outcomes With Effective Management of Pediatric Asthma in Children 6-11 Years of Age

interactivity
Type 2 Inflammation Is a Significant Driver of Pediatric Severe Asthma

Type 2 Inflammation Is a Significant Driver of Pediatric Severe Asthma

Infographic
Is 1 year an appropriate timeframe for deciding if a patient has achieved remission in CRSwNP?

Is 1 year an appropriate timeframe for deciding if a patient has achieved remission in CRSwNP?

expert video
Dr. Giorgio Canonica Regarding Multidisciplinary Approach

Dr. Giorgio Canonica Regarding Multidisciplinary Approach

expert video
ERS 2024 | How Can Biologics Help Achieve Clinical Remission in Children With Severe Asthma?

ERS 2024 | How Can Biologics Help Achieve Clinical Remission in Children With Severe Asthma?

expert video
Pediatric Asthma Trajectory and Clinical Remission

Pediatric Asthma Trajectory and Clinical Remission

expert video

Learning objectives

  • To highlight efficacy data in patients with severe/uncontrolled CRSwNP and co-existing asthma from biologic studies
Tags
quality of lifeairway remodelingexpert insightssymposiummechanism of diseasetype 2 inflammationasthmaCRSwNP
MAT-GLB-2505226 - 1.0 - 09/2025

About this expert

Allergy/Immunology

Zuzana Diamant

MD, PhD

Zuzana Diamant is a pulmonologist and clinical pharmacologist. She is currently a Guest Professor at KUL, Leuven, Belgium. Prof. Diamant also holds the position of Research Director Respiratory & Allergy at QPS-Netherlands, Groningen, Netherlands.

See author’s profile
Zuzana Diamant

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: FinlandChange country/region